206 related articles for article (PubMed ID: 16572114)
1. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
3. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
4. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
5. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Ruilope LM; Segura J
Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
[TBL] [Abstract][Full Text] [Related]
6. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
7. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
[TBL] [Abstract][Full Text] [Related]
8. Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Alexander CM; Lyle PA; Keane WF; Carides GW; Zhang Z; Shahinfar S
Kidney Int Suppl; 2004 Nov; (92):S115-7. PubMed ID: 15485403
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
10. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
11. Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Tershakovec AM; Keane WF; Zhang Z; Lyle PA; Appel GB; McGill JB; Parving HH; Cooper ME; Shahinfar S; Brenner BM
Diabetes Care; 2008 Mar; 31(3):445-7. PubMed ID: 18070995
[TBL] [Abstract][Full Text] [Related]
12. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
13. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
15. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
[TBL] [Abstract][Full Text] [Related]
16. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
[TBL] [Abstract][Full Text] [Related]
17. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
18. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Mohanram A; Zhang Z; Shahinfar S; Lyle PA; Toto RD
Kidney Int; 2008 Mar; 73(5):630-6. PubMed ID: 18094675
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
20. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
